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1. Introduction 
The breast cancer cell genome is remarkably unstable, most likely due to early dysfunction 
of DNA replication, repair or recombination (Roskelley and Bissel, 2002). Accumulation of 
genetic alterations in the cells and/or stroma lead to development of a genetically diverse 
cell population characterized by uncontrolled cell proliferation (Witz, 2002; Gupta et al., 
2006). Therefore, identification of genes that may be responsible for pre-disposition or 
facilitate progression of the disease may contribute to improvement of currently available 
therapeutic approaches in treatment of breast cancer. 
We previously reported the identification, cloning and functional characterization of 
HRPAP20, which encodes for protein designated Hormone Regulated Proliferation-
Associated Protein 20 (accession number: NM_ 014165; Karp et al., 2004). Our observations 
indicated that HRPAP20 is a regulator of proliferation, survival, and invasion in hormone-
responsive breast cancer cells. Moreover, highly invasive, hormone unresponsive breast cell 
lines, such as MDA-MB-231 and tumor specimens of invasive breast adenocarcinomas from 
patients exhibited constitutively elevated levels of HRPAP20 (Karp et al., 2007). Results from 
an independent study conducted by another group suggested that HRPAP20 is a promising 
marker of tamoxifen resistance in women with ER alpha-positive breast tumors (Tozlu-Kara 
et al., 2007). Together, these observations suggested that elevated HRPAP20 may facilitate 
breast cancer progression toward a more malignant phenotype.  
Other studies from our group suggested that an interaction between HRPAP20 and 
calmodulin (CaM) may contribute to HRPAP20-mediated biological effects in tumor cells. 
Furthermore, a basic amino acid residue (K73) within the putative CaM-binding domain of 
HRPAP20 appeared to be important for CaM-binding to the protein. CaM has been shown 
to influence cell cycle control and proliferation in human breast cancer cells by activating 
CaM-kinase II (CaMK II) and MAPK-mediated signaling pathways (Cheung , 1980; Wang et 
al., 1983; Rodriguez-Mora et al., 2005). The recent identification of the ErbB2/HER2/Neu, 
ER-ǂ, and androgen receptor (AR) as CaM-binding proteins, has opened new areas of 
investigation in the regulation of signaling by CaM, particularly in hormone-responsive 
cancer (Cifuentes et al., 2004; Li et al., 2006; Maximciuc et al., 2006).  
Overexpression or constitutive activation of the epidermal growth factor receptor (EGFR) is 
frequently associated with the development and progression of a number of human cancers, 
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including breast cancer (Garcia et al., 2006). HER-2, a member of this receptor tyrosine 
kinase family is overexpressed in 20% -30% of aggressive breast cancers, making it an 
appealing target for prognosis and therapy of the disease (Meric-Bernstam et al., 2006). 
These and other observations have shed light on the fact that the complex role of EGF 
signaling in development and progression of breast cancer is incompletely understood, and 
suggests that gaps exist in our knowledge of its signaling mechanisms. Therefore, 
experiments were conducted to evaluate a potential role of HRPAP20 in EGF-mediated 
signaling in hormone-dependent breast cancer cells.  
Protein kinase C (PKC) is a signaling intermediate that has been linked to EGF stimulation 
in cancer cells. The PKC family of at least 12 serine/threonine protein kinase isoforms, has 
been extensively studied in the regulation of intracellular signaling in response to stimuli 
such as growth factors and hormones (Dekker et al., 1994; Nishizuka et al., 1995; Newton 
1995, and 1997; Mellor et al., 1998). The classical and novel isoforms of PKC are targets for 
phorbol ester compounds, such as TPA, which are a widely studied tumor promoters that 
mimic the actions of diacylglycerol on PKC activation (Barry et al., 2001). Altered expression 
and activity of several PKC isoenzymes has been observed in numerous cancers including 
those affecting the lung, colon, and breast (Gordge et al., 1996; McCracken et al., 2003; 
Gokmen-Polar et al., 2001). It has been reported that PKC-ǂ, -ǅ and -ǆ activate several 
substrates that promote breast tumor cell migration and invasion (Pan et al., 2005; Tan et al., 
2006; Ways et al., 1995). Therefore, it appears that PKC isoforms have distinct roles, which 
relate to their unique localization and/or access to substrates upon activation (Nakagawa et 
al., 2005). Here we show results from experiments conducted to evaluate whether HRPAP20 
is a substrate for PKC. We also demonstrate whether specific PKC isoforms activated by 
EGF stimulation are possibly involved in HRPAP20 phosphorylation and invasion. The 
observations presented in this chapter support the hypothesis that HRPAP20 is an 
important regulator of tumor cell signaling, which may direct malignant progression in 
breast cancer. 
2. Experimental procedures 
2.1 Cell culture and treatments 
The human mammary adenocarcinoma cell line MCF-7 was maintained in DMEM 
supplemented with 10% FBS and penicillin/streptomycin. MCF-7 cells were serum starved 
for 24 hrs in DMEM supplemented with 1% ITS+ (BD Biosciences, Bedford, MA) or 0.1% 
BSA. Quiescent MCF-7 cells were treated with EGF (100 ng/ml) or TPA (20 nM). Treatment 
of MCF-7 cells with Gö6976 (1μM) or Rottlerin (10μM) was carried out 60 min prior to 
stimulation with EGF (100 ng/ml for 30 min). All cells were harvested by washing with ice-
cold PBS and centrifugation.  
2.2 HRPAP20 plasmid construction and site-directed mutagenesis 
The full length HRPAP20 cDNA was ligated into the mammalian expression vector 
pcDNA3.1 using the restriction sites Hind III (5’ end) and Eco-RI (3’ end). The construct was 
sequenced and used for transfection of MCF-7 cells. For bacterial expression of recombinant 
HRPAP20-GST fusion protein, the restriction sites Bam-H1 and Eco-RI were engineered on 
the 5’ and 3’ terminals of the protein frame of HRPAP20 respectively. This oligonucleotide 
was generated by PCR and ligated into the bacterial expression vector PGEX-4T1 
(Amersham Biosciences, Piscataway, NJ). The vectors pcDNA 3.1 and PGEX-4T1 encoding 
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HRPAP20 were used as templates for site-directed mutagenesis. Alanine substitutions were 
performed using the Quick-Change point-mutation kit (Stratagene, La Jolla, CA.). The 
following primers were synthesized to generate the variant HRPAP20 oligonucleotides. 
K73A: 5’-GAGATGTATATGTCAATTCCGCAGATCCGGTGCCTTCCT-3’. R66A: 5’-
ACAAGCTGTTGTCCTTACTAGCAGATGTATATGTCAATTCC-3’. Reverse primers were 
synthesized complementary to the forward primers. The HRPAP20 sequence harboring both 
K73A and R66A site-mutations was generated by using HRPAP20/K73A as a template 
using primers encoding for the R66A mutation. A PCR reaction using cycling conditions 
recommended by the manufacturer was performed. Digestion of the parental plasmid 
template was accomplished using Dpn I. The site mutants were transformed into E-coli, and 
colonies selected on ampicillin-containing soft agar. The individual colonies were grown 
and the plasmid constructs isolated using Qiagen plasmid Mini-prep kit protocol. All 
constructs were sequenced at the University of Cincinnati DNA core facility to confirm the 
amino acid substitutions. The appropriate plasmids were then used for stable transfection of 
cells, or for bacterial expression of variant HRPAP20-GST fusion proteins. 
2.3 Recombinant HRPAP20-GST protein expression and purification 
Recombinant HRPAP20-GST fusion protein was produced by transformation of the 
Escherichia coli strain BL21-Star/p-RARE with the plasmid vector PGEX-4T1 encoding for 
wild-type or variant HRPAP20. The construct was sequenced at the University of 
Cincinnati’s DNA Core Facility prior to transformation. Bacteria transformed with the 
empty vector alone were used to express recombinant GST alone, which was used as an 
assay control. The transformants were grown in complete LB broth, and IPTG (5mM) was 
used to induce protein expression at 27˚C. Following 4 hrs of induction, the cells were lyzed 
by freeze-thawing (3X) and sonication (60V, 5 cycles). Sonicates were centrifuged and GST 
or HRPAP20-GST fusion proteins in the supernatants were purified using glutathione-
agarose (Amersham). Bound GST or HRPAP20-GST protein was eluted by reduced 
glutathione (20mM) and quantitated using Bradford reagent (Biorad, Hercules, CA). The 
purity and molecular weights of the proteins were confirmed by SDS-PAGE followed by 
Coomassie blue staining.  
2.4 CaM-Sepharose binding analysis 
The assay was performed as described previously (Boehning et. al, 2004; Karp et al., 2007). 
Briefly, 20 μl of CaM-Sepharose-4B beads (1.3 mg/ml, Amersham) were equilibriated with 
Buffer A. The equilibriated beads were then blocked for 1 h at room temperature with 1% 
BSA, followed by washing 1X with 500 μl of buffer A. Binding of HRPAP20-GST to CaM 
was evaluated by incubating 5 μg of HRPAP20-GST (wild-type or variant) or GST-only with 
CaM-Sepharose for 1 h at 4°C in buffer A ± CaCl2 (5 mM). Bound protein was eluted using 
SDS sample buffer, followed by SDS-PAGE analysis. Immunoblotting with ǂ-GST or ǂ-
HRPAP20 was used to identify HRPAP20 binding to CaM.  
2.5 In vitro PKC kinase assay employing HRPAP20 as a substrate 
The assay was performed as described in (Li and McNulty et al., 2005). Briefly, 5 μg of the 
fusion protein HRPAP20-GST or GST in 100 μl of PKC buffer containing 20 mM HEPES (pH: 
7.4), 1.67 mM CaCl2,10 mM MgCl2, 1 mM DTT, 1mM ATP and 10 μCi of [Ǆ-32P] ATP was 
used for the kinase reaction. Myristoylated peptide PKC inhibitor (Promega, Madison, WI) 
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was used at a concentration of 100 mM. The kinase reaction was initiated by adding 1 μl of 
PKC (Promega), followed by incubation at 30 ºC for 30 min. A duplicate set of the above 
reactions with the substitution of [Ǆ-32P] ATP with non-radioactive ATP was performed in 
parallel for immunoblotting analysis. The reactions were stopped by placing on ice. The 
fusion proteins were isolated using glutathione agarose, followed by washing, elution and 
SDS-PAGE. The resolved proteins were transfered to PVDF membranes and subjected to 
autoradiography, or immunoblotting with ǂ-GST. The immunoblotted membranes were 
subsequently stripped and reprobed with ǂ-HRPAP20.  
2.6 Immune-complex kinase assay 
Cells were harvested and lyzed using phosphorylation lysis buffer containing 50 mM 
HEPES (pH: 7.5), 150 mM NaCl, 200 µM sodium orthovanadate, 10 mM sodium 
pyrophosphate, 100 mM sodium fluoride, 1 mM EDTA, 1.5 mM MgCl2, 10% glycerol, 1% 
Triton X-100, and protease inhibitors (Rahman et al., 2001). Lysates were 
immunoprecipitated using ǂ-PKC-A3 (Santa Cruz Biotechnology, Santa Cruz, CA) and 
protein-G agarose. Immune-complexes were washed with kinase wash buffer: Tris HCl (50 
mM , pH 7.4), NaF (10 mM), sodium orthovanadate (1 mM), EDTA (0.5 mM), EGTA (0.5 
mM), magnesium chloride (2 mM), leupeptin (10 μg/ml), PMSF (1mM) as previously 
described (Arya et al., 2004). 5 μg of recombinant HRPAP20-GST or GST protein, in a kinase 
reaction buffer containing 20 mM Tris-HCl (pH: 7.4), 10 mM MgCl2 and 1 mM DTT was 
incubated with ATP (1 µM), Ǆ-32P-ATP (10 µCi) for 30 min at 30ºC. The reactions were 
terminated by placing on ice, followed by SDS-PAGE and autoradiography as described in 
previous section.  
2.7 Cell transfection 
MCF-7 cells were transfected with wild-type HRPAP20, R66A, K73A+R66A, or empty vector 
(pcDNA 3.1) alone, according to manufacturer’s protocol using Lipofectamine® (Invitrogen, 
Carlsbad, CA). Following transfection, all cells were subjected to G418 selection (250 µg/ml) 
to generate stably transfected cell lines. Cells were transiently transfected with wild-type 
and dominant-negative PKC-ǅ constructs or empty vector pcDNA3.1, and used in 
experiments 72 hrs after transfection (previously described in Kruger et al., 2003).  
2.8 Co-immunoprecipitation/immunoblotting (co-IP/IB) 
Following treatments, cells were harvested using ice-cold PBS and centrifugation; then lysed 
in a buffer containing 10 mM Tris (pH 7.4), 0.15 M NaCl, 5 mM EDTA and 1% Triton X-100. 
The lysates were pre-cleared with normal rabbit serum and protein G (Upstate, Lake Placid, 
NY), then immunoprecipitated using ǂ-HRPAP20 antiserum (Karp et. al, 2004) and protein 
G. The immunoprecipitates, together with lysates, were resolved using 12% SDS-PAGE gels, 
then immunoblotted with ǂ-CaM (Upstate, Charlottesville, VA.). The membranes were 
subsequently stripped using a buffer containing 62.5 mM Tris (pH 6.8) and 2% SDS, then 
reprobed with ǂ-HRPAP20. 
2.9 Cell invasion analysis 
The invasive capacity of the breast tumor cell lines was measured utilizing an in vitro 
transwell assay (Repesh et al., 1989, Karp et al., 2007). Briefly, 2.5 x 105 cells, in DMEM 
containing 0.1% BSA, were added to the upper well of transwell chambers (Corning Inc., 
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Corning, NY) containing an 8 µm porous membrane, previously coated with type I collagen, 
fibronectin, and Matrigel ® (Becton Dickinson Biosciences, San Diego, CA). Lower chambers 
contained DMEM containing 0.1% BSA and 10% FBS as a chemoattractant. Following 24 hrs, 
invading cells were fixed with 4% paraformaldehyde, stained with crystal violet, and 
counted microscopically (20X magnification) in five random fields/membrane.  
3. Results 
3.1 EGF regulates the interaction between HRPAP20 and CaM in MCF-7 cells 
We previously showed that HRPAP20 interacts with Ca2+/CaM in purified preparations 
and in MCF-7 cells (Karp et al., 2007). To determine whether this interaction was influenced 
by mitogenic stimulation such by EGF, co-immunoprecipitation/ immunoblotting (co-
IP/IB) experiments were conducted using MCF-7 cells. As shown in Fig. 1, CaM co-
immunoprecipitated with HRPAP20 in lysates from control cell suggesting that the two 
proteins existed as a complex in unstimulated cells (time 0) consistent with our previous 
observations. Stimulation with EGF (100 ng/ml) rapidly disrupted the HRPAP20:CaM 
(p<0.05). Thus, mitogenic stimulation appeared to cause dissociation of the protein complex 
that was observed in unstimulated cells. These observations suggest that HRPAP20 may 
function as a signaling intermediate coupled to activation of the EGFreceptor.  
 
 
Fig. 1. EGF stimulation disrupts HRPAP20:CaM in MCF-7 cells. MCF-7 cells, previously 
cultured for 24 hr in serum-free medium, were treated with h-EGF (100 ng/ml). The cells 
were harvested at the indicated times following EGF stimulation. Cell lysates were immuno 
precipitated with ǂ-CaM (upper panel). Membranes were stripped and reprobed with ǂ-
HRPAP20 (middle panel). 10% of total protein used for immunoprecipitation was resolved 
in parallel as an input control and Immunoblotted with ǂ-CaM (lower panel). Densitometric 
analysis of three separate experiments is presented. *p<0.05 vs CTL. 
HRPAP20:CaM interaction requires basic residues K73 and R66 in MCF-7 cells. 
Experiements were conducted to determine which amino acid residues within HRPAP20 
were required for its interaction with CaM. Studies by others (Bagchi et al., 1992) showed 
that certain basic residues within the CaM-binding domains of several interacting proteins 
were required for their interaction. K73, R66, and V70 (hydrophobic) were identified as 
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potential critical residues within HRPAP20 for its interaction with CaM based upon 
comparison with other binding proteins (Fig. 2). 
 
 
Fig. 2. Sequence of the HRPAP20 CaM-binding domain. (A) The amino acid sequence of 
HRPAP20 (residues 54-74) consisting of the predicted CaM-binding motif, was aligned with 
those of other well-characterized CaM-binding proteins. While there is no sequence 
conservation observed in most of the CaM-binding domain, they are characterized by a 
typical positioning of a C-terminal basic residue, preceded by 2-3 hydrophobic residues. (B) 
Sequence alignment of the CaM-binding motif of HRPAP20 with that present in smMLCK 
indicating positions of basic and hydrophobic residues on smMLCK that are critical for 
CaM-binding (Bagchi et al., 1992). Analogous residues within HRPAP20 are boxed and the 
positions numbered. 
Previously, we showed that alanine (ala) substitution of K73 resulted in diminished CaM-
binding of HRPAP20 in MCF-7 cells (Karp et al., 2007). Using site-directed mutagenesis, we 
generated a series of HRPAP20 variants harboring ala substitutions at these residues 
(HRPAP20-K73A, HRPAP20/R66A or HRPAP20/K73A+R66A, and HRPAP20/V70A). The 
proteins were expressed as GST-fusion proteins, then the purified recombinant proteins 
were evaluated by CaM-Sepharose pull-down analysis to assess their capacity to bind to 
CaM. The results indicated that HRPAP20-K73A exhibited ~50% reduction in CaM-binding 
compared to the wild-type protein (Fig. 3). Moreover, ala substitutions at K73 and R66 in 
combination inhibited the HRPAP20:CaM interaction to the same extent as R66A, indicating 
that each of these residues may contribute to CaM-binding (Fig. 3). Alanine substitution of 
the hydrophobic residue V70 did not significantly affect CaM-binding of HRPAP20, 
suggesting that this residue may not be required for in HRPAP20:CaM complex formation 
(results not shown).  
To determine whether the HRPAP20/R66A or HRPAP20/K73A+R66A exhibited a 
diminished interaction with CaM in MCF-7 cells, we conducted co-IP/IB experiments using 
cells stably transfected with HRPAP20, R66A, K73A+R66A, or the empty vector as a control. 
The results demonstrated that CaM co-immunoprecipitated using ǂ-HRPAP20, in MCF-
7/HRPAP20 cells, consistent with our previous observations. In contrast, significantly 
reduced CaM binding was observed in cells transfected with HRPAP20/R66A or 
HRPAP20/K73A+R66A compared to the level observed in wildtype HRPAP20 (Fig. 4A and 
D). The membranes from Fig. 4A were subsequently stripped and reprobed with  
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Fig. 3. K73 and R66 regulate HRPAP20:CaM interact1on in vitro. (A) 5 μg of recombinant 
HRPAP20-GST [wildtype-WT, or HRPAP20 harboring the substitutions K73A, R66A, or 
K73A+R66A] or GST alone were incubated with CaM-Sepharose in the presence of Ca2+ (5 
mM). Eluted proteins were resolved bySDS-PAGE, then immunoblotted with ǂ-GST. 10% of 
each protein used in pull-down assays was evaluated in parallel as an input control. (B) 
Cumulative results of densitometric analysis of three separate experiments is presented. 
*p<0.05 vs. WT. 
ǂ-HRPAP20 to confirm HRPAP20 immunoprecipitation in each of the samples (Fig. 4B). 
Equal concentrations of lysate protein from each of the transfectants were immunoblotted 
using ǂ-CaM as an additional control (Fig. 4C). Together, these results suggested that the 
basic residues K73 and R66 in the CaM-binding motif of HRPAP20 may regulate its 
interaction with CaM in MCF-7 breast cancer cells. 
Shown in Fig. 4E are results from in vitro invasion analysis of cells transfected with 
HRPAP20 and and its variants. Here wildtype HRPAP20 significantly (p<0. 01) increased 
invasion through Matrigel® coated filters in transwell chambers. In contrast, invasion 
observed by the cells expressing the HRPAP20 variants R66A or K73A+R66A did not differ 
from empty vector-transfected controls. These observations indicated that even a partial 
disruption of the HRPAP20:CaM interaction by mutation of the basic residues K73 and R66 
blocked HRPAP20-mediated increase in invasion. Therefore, it is suggested that K73 and 
R66 are likely required to maintain integrity of the HRPAP20:CaM complex, which appears 
to be a requisite for MCF-7 invasion. 
3.2 HRPAP20 is a substrate for PKC 
We previously showed that HRPAP20 is a phosphoprotein and that pharmacological 
inhibition of PKC reduced its phosphorylation in Nb2-11 cells (Karp et al., 2004). 
Experiments to evaluate whether HRPAP20 is phosphorylated by PKC were conducted 
utilizing recombinant HRPAP20-GST fusion protein and catalytically active rat brain PKC, 
in the presence of cofactors and 32P-ATP. As shown in Fig. 5A, HRPAP20 was 
phosphorylated in the presence of PKC (lane 1), but not in its absence (lane 2). Addition of a 
myristoylated peptide substrate, serving as a competitive inhibitor of PKC, inhibited PKC-
mediated phosphorylation of HRPAP20 (lane 3). An equal amount of recombinant GST  
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Fig. 4. Effect of HRPAP20 amino acid substitution (R66A, K73A+R66A) on HRPAP20:CaM 
association and invasion in MCF-7 cells. (A) MCF-7 cells, transfected with empty vector 
(Vector), wildtype HRPAP20 (WT), HRPAP20/R66A (R66A) or HRPAP20/K73A+R66A 
(K73A + R66A) were immunoprecipitated with ǂ-HRPAP20 and immunoblotted with ǂ-
CaM. (B) Membranes were stripped and reprobed with ǂ-HRPAP20. (C) 10% of total protein 
used for immunoprecipitation was resolved in parallel as an input control and 
immunoblotted with ǂ-CaM. (D) Densitometric analysis of three separate experiments is 
presented. *p<0.01 WT vs Vector; p<0.05 WT vs K73A. (E) Cumulative results obtained from 
three separate in vitro invasion experiments. *p<0.01 WT vs Vector. 
incubated with PKC represents a control reaction demonstrating the inability of PKC to 
phosphorylate GST (lane 4). To ensure equal loading of samples, duplicates of the above 
reactions with the substitution of 32P-ATP with non radioactive ATP were resolved in 
parallel and subjected to immunoblotting with ǂ-HRPAP20 (Fig. 5B) or ǂ-GST (Fig. 5C). 
Together, these results suggest that HRPAP20 is a substrate for PKC in vitro. 
3.3 HRPAP20 is phosphorylated by EGF-activated PKC 
There is abundant evidence indicating an important role for EGFR and its ligands in the 
development and progression of human neoplasia (Johnston et al., 2006; Ji et al., 2006; 
Speake et al., 2005; D'Alessio et al., 2010). To evaluate whether PKC-mediated HRPAP20 
phosphorylation is an event that occurrs downstream of EGF stimulation, immune-complex 
kinase assays were performed utilizing PKC immunoprecipitated from lysates of EGF-
treated MCF-7 cells and HRPAP20-GSTas a substrate. The reactions were performed in the 
presence of 32P-ATP, but in the absence of cofactors. As illustrated in Fig. 6A and B, 
HRPAP20 phosphorylation was significantly elevated upon its incubation with PKC 
immunoprecipitated from EGF-treated cells, compared to the level observed in control 
samples from untreated cells. These results suggest that PKC, activated by EGF stimulation 
catalyzed HRPAP20 phosphorylation.  
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Fig. 5. Phosphorylation of HRPAP20 by PKC. (A) Recombinant HRPAP20-GST (lanes 1-3) or 
GST alone (lane 4) were incubated at 30°C in the presence (+) or absence (-) of purified rat 
brain PKC or a PKC inhibitor (myristoylated PKC peptide inhibitor, 100 μM) in the presence 
of [Ǆ-32P] ATP. Samples were resolved by SDS-Page followed by autoradiography. (B) 
Duplicates of reactions in (A), but without [Ǆ-32P] ATP, were immunoblotted with ǂ-
HRPAP20. (C) Membranes from (B) were stripped, then reprobed with ǂ-GST. 
 
 
Fig. 6. HRPAP20 is phosphorylated by PKC activated subsequent to EGF stimulation in 
MCF-7 cells. (A) PKC from quiescent or EGF-treated MCF-7 cells was immunoprecipitated, 
then incubated with recombinant HRPAP20-GST or GST in the presence of Ǆ-32P-ATP, 
followed by SDS-PAGE and autoradiography. A representative autoradiograph indicating 
the level of HRPAP20 phosphorylation is shown. (B) Cumulative results from three 
independent experiments analyzed by densitometry are presented. *p<0.01 vs CTL. 
3.4 PKC-δ phosphorylates HRPAP20 subsequent to EGF stimulation and is required 
for invasion in MCF-7 cells 
The role of various PKC isoforms in the process of tumor progression in the mammary 
epithelium is only partially understood. However, several studies support a role for PKC-ǅ 
in breast tumor progression (McCracken et al., 2003; Nabha et al., 2005). Moreover, PKC-ǅ 
has been shown to regulate the activation of MMP-9 in breast tumor cells; an effect also 
observed in MCF-7 cells stably expressing elevated levels of HRPAP20 (Karp et al., 2007). 
Therefore, experiments were conducted to determine whether PKC-ǅ phosphorylated of 
HRPAP20 following EGF stimulation in this cell line. Quiescent MCF-7 cells were subjected 
to treatment with Gö6976, a pharmacological inhibitor of classic PKC isozymes, or Rottlerin, 
with specificity directed toward the PKC-ǅ isoform. The results from immunecomplex 
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kinase analysis indicated that while Gö6976 did not affect EGF-stimulated HRPAP20 
phosphorylation, Rottlerin nearly completely blocked this effect (Fig. 7A). These results 
suggested that PKC-ǅ, activated by EGF stimulation, may be responsible for the 
downstream phosphorylation of HRPAP20.  
To further investigate whether PKC-ǅ catalyzed HRPAP20 phosphorylation, MCF-7 cells 
were transiently transfected with constructs encoding a constitutively active wild-type (WT) 
PKC-ǅ, a kinase inactive/dominant negative PKC-ǅ (DN), or with the empty vector. 
Transfectants were treated with EGF and evaluated using immune-complex kinase analysis. 
The results indicated that EGF stimulated substantial HRPAP20 phosphorylation in cells 
expressing WT-PKC-ǅ (Fig. 7B). However, expression of DN- PKC-ǅ almost completely 
abolished this effect. Together, these results support the hypothesis that PKC-ǅ mediates 
phosphorylation of HRPAP20 and that this effect may underlie EGF stimulated actions. 
To determine whether HRPAP20 phosphorylation affected cell invasion in vitro, invasion 
analysis was conducted using MCF-7 cells co-transfected with HRPAP20 and dominant 
negative PKC-ǅ. As shownin Fig. 7C, co-expression of dominant negative PKC-ǅ with 
HRPAP20, caused a significant reduction of MCF-7 cell invasion, compared to the level 
observed in cells transfected with HRPAP20 alone. These results suggested that activated 
PKC-ǅ is required to regulate HRPAP20, ultimately resulting in stimulating increased 
invasiveness in breast cancer cells.  
 
 
Fig. 7. PKC-ǅ catalyzes EGF-stimulated HRPAP20 phosphorylation and contributes to 
invasion. (A) Quiescent MCF-7 cells were pre-treated with PKC inhibitors Gö6976 (1 μM) or 
Rottlerin (10 μM), followed by the addition of EGF (100 ng/ml). PKC was 
immunoprecipitated and incubated with recombinant HRPAP20-GST in the presence of Ǆ-
32P-ATP. A representative autoradiograph showing HRPAP20 phosphorylation is presented. 
(B) MCF-7 cells were transiently transfected with empty vector (Vector), wild-type (WT) or 
dominant negative PKC-ǅ (DN). Cells were then treated with EGF, followed by 
immunecomplex kinase analysis. (C) MCF-7 cells were transfected with empty vector 
(Vector), HRPAP20, or HRPAP20 and PKC-ǅ (DN), then evaluated by in vitro invasion 
assay. Cumulative results from three independently performed experiments are presented. 
*p<0.01 (HRPAP20 vs. Vector or HRPAP20 + DN-PKC-ǅ). 
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3.5 Effect of phosphorylation on HRPAP20: CaM interaction 
Numerous previous studies have reported that post-translational modification may alter 
protein-protein interactions. Therefore, whether HRPAP20 phosphorylation affected its 
interaction with CaM was investigated. Experiments were conducted using MCF-7 cells 
treated with the phorbol ester, TPA, an activator of PKC. The HRPAP20:CaM interaction in 
these cells was evaluated by co-IP analysis. As demonstrated in Fig. 8A, TPA rapidly 
stimulated a significant (p<0.01) reduction in HRPAP20:CaM complex suggesting that PKC-
catalyzed phosphorylation of HRPAP20 may reduce its binding capacity to CaM. Moreover, 
this observation correlated with the pattern of HRPAP20:CaM disruption observed upon 
EGF stimulation in these cells. 
Furthermore, CaM Sepharose pull-down experiments were conducted to determine whether 
PKC-mediated phosphorylation of HRPAP20 affected its CaM-binding in vitro. The results 
obtained indicated that HRPAP20, phosphorylated by PKC prior to incubation with CaM, 
exhibited markedly reduced HRPAP20:CaM complex formation, in contrast to that observed 
with the native protein (Fig. 8B). This observation is consistent with our previous results 
suggesting that PKC likely regulates HRPAP20:CaM association. Taken together, the results 
suggest that HRPAP20 may modulate signaling involved in growth factor/hormone-
responsive cancers by associating with PKC and CaM.  
 
 
Fig. 8. HRPAP20:CaM is likely regulated by PKC-catalyzed phosphorylation. (A) Serum 
starved MCF-7 cells were treated with TPA (20 nM). Cells were harvested at the indicated 
time points, followed by immunoprecipitation of lysates using ǂ-HRPAP20, then 
immunoblotted with ǂ-CaM (upper panel). Membranes were stripped and reprobed with ǂ-
HRPAP20 (middle panel). 10% of total protein used for immunoprecipitation was resolved 
in parallel as an input control and immunoblotted with ǂ-CaM (lower panel). Densitometric 
analysis of three separate experiments is presented. *p<0.05 vs. 0 min. (B) 5 μg of 
recombinant HRPAP20-GST was phosphorylated in vitro using rat brain PKC, then 
subjected to CaM- pulldown assay. A representative immunoblot using ǂ- is shown. 
4. Discussion 
Tumor cell responses to extracellular stimuli includes activation of kinase pathways and 
alteration of protein-protein interactions, ultimately resulting in modulation of biological 
responses leading to progression of the disease. Since previous observations implicated a 
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role for HRPAP20 in breast tumor proliferation and invasion, it was important to investigate 
the mechanisms by which this protein participated in tumor cell signaling.  
Previously we showed that HRPAP20 and CaM interacted in vitro and in MCF-7 cells (Karp 
et al., 2007). We therefore sought to investigate whether this interaction contributed to 
tumor signaling and whether it was subject to regulation by growth factor stimulation. 
Recent studies have broadened the view of signal transduction to encompass a complex 
networks, which allow interaction between discrete signaling pathways with EGFR as a key 
unit for integration of multiple stimuli (Prenzel et al., 2000). CaM has been shown to bind to 
the EGFR, as well as modulate EGF-stimulated signaling leading to tumor progression. It 
was therefore important to investigate whether HRPAP20 was subject to regulation 
downstream of EGFR activation in tumor cells. Using co-IP/IB, we showed that HRPAP20 
resides within a complex with CaM in quiescent MCF-7 cells. Stimulation with EGF caused a 
significant reduction in HRPAP20:CaM association. These results suggest that the 
HRPAP20:CaM complex is likely regulated by EGF, and may serve as a potentially 
important step in growth factor-stimulated cell signaling.  
To investigate which specific amino acid residues within HRPAP20 participate in its 
interaction with CaM, we compared the sequence of the CaM-binding domain of HRPAP20 
to binding domains present in other CaM interacting proteins. This assessment revealed that 
several basic and hydrophobic amino acids were interspersed within the HRPAP20 CaM-
binding motif at positions analogous to those found to be important for other CaM-binding 
proteins (Bagchi et al., 1992; Fitzsimons et al., 1992). Following generation of HRPAP20 
variants harboring ala substitutions at suspected key locations, experiments were conducted 
to evaluate HRPAP20:CaM binding of the altered proteins. Results from these suggested 
that the basic residues, K73 and R66, located near the C-terminus of the CaM-binding 
domain of HRPAP20, may be critical for its interaction with CaM. 
Bioinformatic analysis of the wildtype and variant HRPAP20 amino acid sequences 
indicated that both K73A and R66A substitutions most likely altered the length and stability 
of ǂ-helices within the protein. Notably, K73 was predicted to be responsible for a bend in 
the strand following the ǂ-helix that constituted the CaM-binding motif of HRPAP20 
(www.igb.uci.edu/tools/scratch.html; http://npsa-pbil.ibcp.fr/cgi-bin/secpred_hnn.pl; 
NNPredict Query server; and http://distill.ucd.ie/porter/). Moreover, alanine substitution of 
R66 reduced the number of its residue contacts, hence potentially destabilizing the helix and 
potentially affecting its ability to bind CaM. 
To investigate whether abrogation of HRPAP20:CaM interaction by R66A or K73A+R66A 
substitutions affected tumor cell invasion, we compared the invasive capacity of MCF-7 cells 
transfected with either wildtype HRPAP20 or its variants. In contrast to the wildtype 
protein, HRPAP20/R66A or HRPAP20/K73A+R66A failed to increase invasion. Therefore, 
consistent with our previous observations, the results suggest reports an upstream 
requirement for CaM-binding of HRPAP20 that is coupled to tumor invasiveness. 
Protein phosphorylation has been known to play a significant role in the regulation of 
numerous aspects of cellular function such as growth, metabolism, motility, survival, and 
apoptosis. Moreover, numerous protein-protein interactions have been shown to be 
regulated by phosphorylation (Cho et al., 2004). Since HRPAP20 appears to complex with 
CaM and contains three consensus motifs for PKC catalyzed phosphorylation, it was 
hypothesized that HRPAP20 function may be regulated by CaM-binding and 
phosphorylation. EGF has been reported to activate PKC in MCF-7 cells (Mueller et al., 
1997). Increased levels of PKC expression and activation have been associated with 
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malignant transformation in a number of cell lines including breast, lung and gastric 
carcinomas (O’Brian et al., 1989; Takenaga et al., 1986; Schwartz et al., 1993). These 
observations suggest that PKC contributes to tumor progression and may serve as a 
therapeutic target for treatment of breast cancer. 
We proposed that EGF stimulation in MCF-7 cells may subsequently induce HRPAP20 
phosphorylation, following activation of PKC. To test this hypothesis, we conducted 
immune-complex kinase assays utilizing recombinant HRPAP20 and PKC 
immunoprecipitated from MCF-7 cells treated with/without EGF. Indeed, the results 
generated suggest that PKC immunoprecipitated from EGF-treated MCF-7 cells catalyzed 
HRPAP20 phosphorylation. Therefore, it appeared likely that EGF stimulation, which 
subsequently activates PKC, may lead to downstream phosphorylation of HRPAP20.  
Results provided by others have suggested that the PKC-ǅ isoform is a positive regulator of 
metastatic progression and a survival factor in breast cancer (McCracken et al., 2003). 
Several reports now suggest that PKC-ǅ plays an important role in EGFR-mediated breast 
tumor progression as an important contributor to the later stages of cell migration (Kruger 
et al., 2003). Results presented here from immune-complex kinase assays suggested that 
while PKC-ǅ inhibition by rottlerin abrogated EGF-stimulated HRPAP20 phosphorylation, 
inhibition of conventional PKC isoforms with Gö6976 had no effect. This suggests that PKC-
ǅ but not -ǂ, -ǃ, or –Ǆ may mediate EGF-induced HRPAP20 phosphorylation. To further 
investigate HRPAP20 phosphorylation, immune-complex kinase assays were conducted 
using PKC immunoprecipitated from MCF-7 cells transiently transfected with wildtype or 
dominant negative PKC-ǅ. The results indicated that while expression of wildtype PKC-ǅ 
enhanced EGF-mediated HRPAP20 phosphorylation, the dominant negative PKC-ǅ variant 
failed to produce this effect. Together, the results strongly indicate that PKC-ǅ, activated 
upon EGF stimulation, may be responsible for HRPAP20 phosphorylation.  
In breast cancer cell lines and fibroblasts, EGF stimulation has been shown to induce 
chemotactic migration with significant involvement of PKC ǂ, Ǉ, ǅ and ǆ (Rabinovitz et al., 
1999; Joberty et al., 2000; Iwabu et al., 2004). To determine whether PKC-ǅ is required for the 
observed HRPAP20-mediated increase in MCF-7 cell invasion, in vitro invasion experiments 
were conducted using cells co-expressing HRPAP20 and the dominant negative PKC-ǅ 
construct. It was observed that cells co-expressing DN PKC-ǅ with HRPAP20, failed to 
increase invasion above levels found in empty vector transfectants. These observations 
suggest that HRPAP20 phosphorylation by PKC-ǅ may be required for breast tumor cell 
invasion. Together, the results suggest that HRPAP20 may participate in EGF-stimulated 
signaling pathways in tumor cells, and that the effects of HRPAP20 may be regulated at 
least in part by CaM and PKC-catalyzed phosphorylation. 
Phosphorylation has been shown to affect the CaM-binding affinity of several proteins. The 
myristoylated alanine rich C kinase substrate (MARCKS) protein and its homologue, 
MARCKS related protein (MRP), have been shown to bind CaM in a Ca2+-dependent 
manner. Importantly, their interaction with CaM was diminished upon phosphorylation by 
PKC (Porumb et. al, 1997; Mc Ilroy et al., 1991). Several hormones produce an increase in 
intracellular Ca2+, which facilitates CaM-binding to its target proteins and the consequent 
activation of PKC. These and the previous observations implicate that activation of PKC by 
various external stimuli may result in release of its substrates from CaM-bound pools by 
virtue of their phosphorylation. On the other hand, this may, in effect, result in the increase 
in intracellular levels of freely accessible CaM, leading to amplification of CaM-dependent 
processes.  
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Based on these observations and results indicating that HRPAP20 was a substrate for PKC 
downstream of EGF stimulation, we investigated whether phosphorylation affected CaM-
binding of HRPAP20. Our results indicated that TPA caused a disruption of the 
HRPAP20:CaM complex in MCF-7 cells, in a manner similar to that observed upon EGF 
stimulation. In addition results from CaM-Sepharose pull-down assays illustrated that the 
phosphorylated form of HRPAP20 exhibited diminished CaM-binding in vitro, compared to 
the unphosphorylated protein.  
We suggest that EGF stimulation, which activates PKC, may subsequently result in 
HRPAP20 phosphorylation. Furthermore, our observations clearly indicate that PKC-
catalyzed phosphorylation of HRPAP20 regulates HRPAP20:CaM complex formation, and 
may potentially serve as an activation intermediate that leads to tumor invasion. Finally, our 
results suggest that a requirement of PKC-ǅ together with elevated HRPAP20 as factors that 
enhance breast cancer cell invasion. These observations provide additional clues with regard 
to the mechanism of regulation of HRPAP20 function and invasion in breast cancer. Thus, 
further studies on the role of HRPAP20 in tumor progression may reveal a hitherto 
unsuspected target for therapy of breast cancer. 
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